Protocol Ledger

NCT03496883 · Phase III · ACTIVE NOT RECRUITING

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Interventional Phase III clinical trial protocol NCT03496883 sponsored by Joseph Broderick, MD in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-03 Enrollment: 860 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03496883
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)860 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03496883
Protocol FieldVerified Registry Value
NCT IdentifierNCT03496883
Consolidated Lead SponsorJoseph Broderick, MD
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment860 participants (ESTIMATED)
Registered Start Date2021-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03496883
Hospital Research SiteLocationSite Profile
Mills-Peninsula Medical CenterBurlingame, CAOpen Hospital Dossier ->
Kaiser Permanente Downey Medical CenterDowney, CAOpen Hospital Dossier ->
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI